FDA approves two Dako assays Dako, an Agilent Technologies company, announced it has received approval from the FDA for the addition of Kadcyla in the labeling of two Dako companion diagnostic assays. Kadcyla is Genentech's new medicine for patients with HER2-positive metastatic breast cancer who have received prior treatment with Genentech's cancer medicine Herceptin and a taxane chemotherapy. The two assays are Dako's HercepTest and HER2 IQFISH pharmDx.
News For A From The Last 14 Days
Check below for free stories on A the last two weeks.